Temasek leads $85M round for Chinese biotech aiming for cheaper, faster, better CAR-T therapies
The landmark approvals of CAR-T therapies have been heralded, but emerging supply chain hurdles catalyzed by the complex manufacturing process for the cellular therapies have pushed makers to look for ways to streamline and quicken the process to augment product volumes and shore up adoption. China’s Gracell is looking to capitalize on these technical wobbles, with its crop of new, low cost cell therapies, with the backing of storied investor Temasek.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters